Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells. A potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension

Microvascular Research

Volumn 80, Issue 3, 2010, Pages 349-354

  Star, Gregory P ^a,b   Giovinazzo, Michele ^a,b   Langleben, David ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Bone morphogenic protein 9; Endothelin; Endothelium derived factors; Hypertension; Pulmonary; Pulmonary endothelium

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 9; ENDOTHELIN 1; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LUNG ENDOTHELIUM; MICROVASCULATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIN-1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GROWTH DIFFERENTIATION FACTOR 2; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICROVESSELS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, ENDOTHELIN B; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 78249258681     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.05.010     Document Type: Article

References (37)

1. Brown M.A., et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J. Biol. Chem. 2005, 280:25111-25118.
2. Castanares C., et al. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J. Cell Sci. 2007, 120:1256-1266.
3. Christman B.W., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J. Med. 1992, 327:70-75.
4. David L., et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 2008, 102:914-922.
5. David L., et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007, 109:1953-1961.
6. Deng Z., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenic protein receptor-II gene. Am. J. Hum. Genet. 2000, 67:737-744.
7. B receptors. J. Appl. Physiol. 1996, 81:1510-1515.
8. Giaid A., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J. Med. 1993, 328:1732-1739.
9. Harrison R.E., et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J. Med. Genet. 2003, 40:865-871.
10. Hassel S., et al. Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004, 4:1346-1358.
11. Katoh Y., Katoh M. Comparative integromics on BMP/GDF family. Int. J. Mol. Med. 2006, 17:951-955.
12. Lane K.B., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. 2000, 26:81-84.
13. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin. Chest Med. 2007, 28:117-125.
14. Langleben D., et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 2006, 129:689-695.
15. Long L., et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009, 119:566-576.
16. Machado R.D., et al. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54:S32-S42.
17. Machado R.D., et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 2001, 68:92-102.
18. Miller A.F., et al. Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver. J. Biol. Chem. 2000, 275:17937-17945.
19. Morrell N.W. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?. Proc. Am. Thorac. Soc. 2006, 3:680-686.
20. Morrell N.W., et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54:S20-S31.
21. Newman J.H., et al. Narrative review: The enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann. Intern. Med. 2008, 148:278-283.
22. Nohe A., et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 2002, 277:5330-5338.
23. Pinckard R.N., et al. Molecular heterogeneity of platelet-activating factor produced by stimulated human polymorphonuclear leukocytes. Biochem. Biophys. Res. Commun. 1984, 122:325-332.
24. Scharpfenecker M., et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 2007, 120:964-972.
25. Seay U., et al. Transforming growth factor-beta-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J. Pharmacol. Exp. Ther. 2005, 315:1005-1012.
26. Senta H., et al. Cell responses to bone morphogenetic proteins and peptides derived from them: biomedical applications and limitations. Cytokine Growth Factor Rev. 2009, 20:213-222.
27. Shintani M., et al. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J. Med. Genet. 2009, 46:331-337.
28. Song J.J., et al. Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology 1995, 136:4293-4297.
29. Star G.P., et al. Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascul. Pharmacol. 2009, 50:45-50.
30. Stewart D.J., et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann. Intern. Med. 1991, 114:464-469.
31. Tanaka Y., et al. The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. J. Clin. Invest. 1996, 98:434-442.
32. Teichert-Kuliszewska K., et al. Bone morphogenic protein receptor-2 signalling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ. Res. 2006, 98:209-217.
33. Trembath R.C., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J. Med. 2001, 345:325-334.
34. Tuder R.M., et al. Development and pathology of pulmonary hypertension. J. Am. Coll. Cardiol. 2009, 54:S3-S9.
35. Upton P.D., et al. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J. Biol. Chem. 2009, 284:15794-15804.
36. Upton P.D., Morrell N.W. TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases. Curr. Opin. Pharmacol. 2009, 9:274-280.
37. Yu P.B., et al. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J. Biol. Chem. 2005, 280:24443-24450.